Sanofi Dengue Vaccine Succeeds in Reducing Disease, Study Shows
This article is for subscribers only.
Sanofi’s experimental dengue vaccine succeeded in a study in reducing the mosquito-borne disease, moving the company closer to introducing the first inoculation against an illness that threatens almost half of the world’s population.
Results from 10,275 children showed a 56 percent reduction of dengue-disease cases, Paris-based Sanofi said in an e-mailed statement today. The initial safety data from the late-stage study are consistent with previous trials, the company said. Sanofi didn’t disclose how well the vaccine protected against each of dengue’s four strains.